Our Research
Success

Every year over 60 children and teenagers in the UK are diagnosed with rhabdoymosarcoma (RMS), yet treatment regimes and survival rates have remained largely unchanged for decades. Radiotherapy is an important component of treatment for…

The development of ground-breaking technologies to facilitate the introduction of a new era of whole genome sequencing will revolutionise childhood leukaemia research and diagnosis. Whole genome sequencing has identified many genomic abnormalities of clinical relevance…

In childhood acute lymphoblastic leukemia (ALL), residual leukemic cells persisting in the bone marrow after the first 4 weeks of therapy are termed as minimal residual disease (MRD). These cells are presumed to resistant to…

Medulloblastoma (MB) is the most common malignant brain tumour in children. More than one third of children with MB do not survive and essentially 100% of survivors face high risk of recurrence and significant long-term…

Obesity is recognised by the World Health Organisation as a global epidemic. Many links have been made between obesity and poorer outcomes for patients diagnosed with a range of diseases, including cancer. In particular, obese…

Neuroblastoma is a very serious cancer, comprising around one tenth of childhood tumours, with around 15 cases in 100 being incurable. Neuroblastoma is unusual as depending on the age of patient diagnosis, cure rates differ…

Treatments for acute lymphoblastic leukaemia (ALL) typically involve chemotherapy, usually in combination with steroids. There remains a need to develop novel therapies or enhance existing approaches to treatment, especially in patients with relapsed disease. A…

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam cursus vel sem nec dictum. Cras finibus magna quis metus dignissim elementum. Proin vitae ornare felis, non dictum diam. Aliquam non erat enim. Vestibulum velit libero,…

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam cursus vel sem nec dictum. Cras finibus magna quis metus dignissim elementum. Proin vitae ornare felis, non dictum diam. Aliquam non erat enim. Vestibulum velit libero,…

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam cursus vel sem nec dictum. Cras finibus magna quis metus dignissim elementum. Proin vitae ornare felis, non dictum diam. Aliquam non erat enim. Vestibulum velit libero,…

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam cursus vel sem nec dictum. Cras finibus magna quis metus dignissim elementum. Proin vitae ornare felis, non dictum diam. Aliquam non erat enim. Vestibulum velit libero,…

ALL is the commonest cancer of childhood and treatment related toxicity and relapse are important therapeutic challenges. To further improve outcome new, non-toxic, targeted therapies need to be developed. These may be targeted to the…